Subject Expert Committee of CDSCO recommended amendment of indication of Typhoid Vi conjugate vaccine of Zydus Lifesciences to include the age group of 45-65 years for single dose only.
Earlier, Zydus Lifesciences had presented its proposal for grant of permission for the additional indication of Typhoid Vi conjugate vaccine for age group 45-65 years along with the Phase III clinical trial report.
Typhoid Vi conjugate vaccine of Zydus available as a brand name, Zyvac Tcv-PFS Vaccine which is an active immunizing agent. It is given to prevent typhoid fever caused by certain bacteria called Salmonella Typhi. It is usually administered at least 2 weeks prior to expected exposure to S. Typhi.
Its effectiveness lasts for around 3 years from the time of vaccination. Booster injection is required every 3 years to provide continued immunity.
